

**IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE**

AMGEN INC.,	:	
	:	
	:	
Plaintiff,	:	
	:	
v.	:	
AUROBINDO PHARMA LTD., et al.	:	C.A. No. 16-853 (MSG)
	:	CONSOLIDATED
	:	
Defendants.	:	
	:	
	:	
	:	

AMGEN INC.,	:	
	:	
	:	
Plaintiff,	:	
	:	
v.	:	
CIPLA LIMITED and CIPLA USA, INC.,	:	C.A. No. 16-880 (MSG)
	:	
	:	
Defendants.	:	
	:	
	:	
	:	

CONSENT JUDGMENT

Plaintiff Amgen Inc. (“Plaintiff”) and Defendants Cipla Limited (“Cipla Ltd.”), and Cipla USA, Inc. (“Cipla USA”) (Cipla Ltd. and Cipla USA collectively referred to herein as “Defendants”), the parties in Civil Action No. 16-cv-880-MSG and C.A. No. 16-853-MSG CONSOLIDATED, have agreed to terms and conditions representing a negotiated settlement of

this action and have set forth those terms and conditions in an executed Settlement Agreement (the “Settlement Agreement”); Now the Parties, by their respective undersigned attorneys, hereby stipulate and consent to entry of judgment and an injunction in this action as follows:

IT IS this ____ day of _____ 2018

ORDERED, ADJUDGED AND DECREED as follows:

1. This Court has jurisdiction over the subject matter of the above action and has personal jurisdiction over the parties.
2. As used in this Consent Judgment, (i) the term “Defendants’ Product” shall mean a drug product sold, offered for sale or distributed pursuant to Abbreviated New Drug Application No. 208915; and (ii) the term “Affiliate” shall mean any entity or person that, directly or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with Defendants for purposes of this definition, “control” (a) means ownership, directly or through one or more intermediaries, of (1) more than fifty percent (50%) of the shares of stock entitled to vote for the election of directors, in the case of a corporation, or (2) more than fifty percent (50%) of the equity interests in the case of any other type of legal entity or status as a general partner in any partnership, or (b) any other arrangement whereby an entity or person has the right to elect a majority of the Board of Directors or equivalent governing body of a corporation or other entity or the right to direct the management and policies of a corporation or other entity.
3. Defendants have admitted that Amgen’s United States Patent Number 9,375,405, (the “Amgen Patent”) is enforceable and valid.
4. Except as otherwise provided in the Settlement Agreement, Defendants have admitted, for themselves and their Affiliates, that the manufacture, use, sale, offer to sell, and

distribution of the Defendants' Product in the United States, and importation of Defendants' Product into the United States, would infringe the Amgen Patent.

5. Except to the extent specifically authorized in the Settlement Agreement, Defendants and their Affiliates, including any of their successors and assigns, are enjoined under the Amgen Patent, including any extensions and/or additional periods of exclusivity to which Amgen is or becomes entitled, from infringing the Amgen Patent by making, having made, using, selling, offering to sell, or distributing the Defendants' Product in the United States, or importing the Defendants Product into the United States.

6. Except as the Parties have provided in their Settlement Agreement by virtue of this Consent Judgment all other claims and demands for relief prayed for by Amgen against Defendants in this action are deemed to be satisfied.

7. Except as the Parties have provided in their Settlement Agreement, by virtue of this Consent Judgment all other claims and demands for relief prayed for by Defendants in this action are deemed to be satisfied.

8. Defendants have agreed that in the event of breach or violation by Defendants of the terms of this Consent Judgment, jurisdiction and venue for an action for a preliminary injunction against the breaching conduct exists in this District Court, and Defendants hereby waive any and all defenses based on personal jurisdiction and venue.

9. Compliance with this Consent Judgment may be enforced by Amgen and its successors in interest, or assigns, as permitted by the terms of the Settlement Agreement.

10. This Court retains jurisdiction to enforce or supervise performance under this Consent Judgment and the Settlement Agreement.

11. The above action, including any counterclaims or affirmative defenses is dismissed with prejudice and without costs, disbursements or attorneys' fees to any party.

Dated: February 28, 2018

BAYARD P.A.

/s/ Stephen B. Brauerman
Stephen B. Brauerman (No. 4952)
Sara E. Bussiere (No. 5725)
600 N. King Street, Suite 400
P.O. Box 25130
Wilmington, DE 19899
(302) 655-5000
sbrauerman@bayardlaw.com
sbussiere@bayardlaw.com

OF COUNSEL:

Anil H. Patel
(Anil.Patel@klgates.com)
K&L Gates LLP
1000 Main St., Suite 2550
Houston, TX 77002
P: +1.713.815.7300
F: +1.713.815.7301

Peter Giunta
(Peter.Giunta@klgates.com)
K&L Gates LLP
599 Lexington Avenue
New York, NY 10022-6030
P: +1.212.536.3900
F: +1.212.536.3901

Michael J. Freno
(Michael.Freno@klgates.com)
Harold S. Storey
(Harold.Storey@klgates.com)
Elizabeth J. Weiskopf
(Elizabeth.Weiskopf@klgates.com)
Jenna Bruce
(Jenna.Bruce@klgates.com)
K&L GATES LLP
925 Fourth Avenue, Suite 2900
Seattle, WA 98104-1158
P: +1.206.623.7580
F: +1.206.623.7022

*Attorneys for Defendant Cipla
Limited and Cipla USA, Inc.*

MORRIS, NICHOLS, ARSHT & TUNNELL LLP

/s/ Jack B. Blumenfeld
Jack B. Blumenfeld (#1014)
Maryellen Noreika (#3208)
1201 North Market Street
P.O. Box 1347
Wilmington, DE 19899
(302) 658-9200
jblumenfeld@mnat.com
mnoreika@mnat.com

OF COUNSEL:

John D. Murnane
Joshua I. Rothman
Alicia A. Russo
FITZPATRICK, CELLA, HARPER & SCINTO
1290 Avenue of the Americas
New York, NY 10104
(212) 218-2100

Attorneys for Plaintiff Amgen Inc.

IT IS SO ORDERED this 5th day of March, 2018.



THE HON. MITCHELL S. GOLDBERG
United States District Court Judge